Medindia

X

Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance

Friday, October 5, 2007 General News J E 4
Advertisement
NEW YORK, Sept. 26 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX) announced today that it will conduct a conference call todiscuss a strategic alliance surrounding one of its Phase II portfolioproducts for a territory outside the US.

The call will take place today, Wednesday, September 26, 2007, at 8:30amEDT. Michael S. Weiss, Chairman and CEO of Keryx Biopharmaceuticals will hostthe call.

Interested parties may participate in the call by dialing 1-877-719-9796(U.S.), 1-719-325-4777 (outside the U.S.), call-in ID: KERYX. The audiorecording of the conference call will be available for replay athttp://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, developmentand commercialization of medically important, novel pharmaceutical productsfor the treatment of life-threatening diseases, including diabetes and cancer.Keryx's lead compound under development is Sulonex(TM) (sulodexide),previously referred to as KRX-101, a first-in-class, oral heparinoid compoundfor the treatment of diabetic nephropathy, a life-threatening kidney diseasecaused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinicalprogram under a Special Protocol Assessment with the Food & DrugAdministration. Additionally, Keryx is developing Zerenex(TM), an oral,inorganic, iron-based compound that has the capacity to bind phosphate andform non-absorbable complexes. Zerenex is currently in Phase II clinicaldevelopment for the treatment of hyperphosphatemia (elevated serum phosphorouslevels) in patients with end- stage renal disease. Keryx is also developingclinical-stage oncology compounds, including KRX-0401 (perifosine), a novel,first-in-class, oral modulator of Akt, a pathway associated with tumorsurvival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types.Keryx also has an active in-licensing and acquisition program designed toidentify and acquire additional drug candidates. Keryx is headquartered in NewYork City.KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965

SOURCE Keryx Biopharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Keryx Biopharmaceuticals, Inc. Enters into Licensi...
S
Osprey Pharmaceuticals Names Jack M. Anthony as CE...